Compound
D0976 | lasalocid sodium
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 1.14±0.07 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 1.38 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 1.30±0.29 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
 |
Danger |
Aggregated GHS information provided by 193 companies from 2 notifications to the ECHA C&L Inventory. Reported as not meeting GHS hazard criteria by 1 of 193 companies. For more detailed information, please visit ECHA C&L website Of the 1 notification(s) provided by 192 of 193 companies with hazard statement code(s): H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P264, P270, P301+P310, P321, P330, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| 2,3-Cresotic acid, 6-(7-(5-ethyl-5-(5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl)tetrahydro-3-methyl-2-furyl)-4-hydroxy-3,5-dimethyl-6-oxononyl)-, monosodium salt. (-)- | 25999-20-6 | 6-(7-(5-Ethyl-5-(5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl)tetrahydro-3-methyl-2-furanyl)-4-hydroxy-3,5-dimethyl-6-oxononyl)-2-hydroxy-3-methylbenzoic acid monosodium salt, (2R-(2alpha(2S*(3R*,4S*,5S*,7R*),3S*,5S*),5alpha,6beta))- |
| AKOS025311506 | Avatec | BDBM79589 |
| Benzoic acid, 6-((3R,4S,5S,7R)-7-((2S,3S,5S)-5-ethyl-5-((2R,5R,6S)-5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl)tetrahydro-3-furanyl)-4-hydroxy-3,5-dimethyl-6-oxononyl)-2-hydroxy-3-methyl-, monosodium salt | Benzoic acid, 6-(7-(5-ethyl-5-(5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl)tetrahydro-3-methyl-2-furanyl)-4-hydroxy-3,5-dimethyl-6-oxononyl)-2-hydroxy-3-methyl-, monosodium salt, (2R-(2alpha(2S*(3R*,4S*,5S*,7R*),3S*,5S*),5alpha,6beta))- | Benzoic acid,6-[(3R,4S,5S,7R)-7-[(2S,3S,5S)-5-ethyl-5-[(2R,5R,6S)-5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl]tetrahydro-3-methyl-2-furanyl]-4-hydroxy-3,5-dimethyl-6-oxononyl]-2-hydroxy-3-methy |
| Bovate 20 | Bovatec | Bovatec 150FP |
| CAS-25999-20-6 | CHEMBL1489769 | CS-5930 |
| DSSTox_CID_25895 | DSSTox_GSID_45895 | DSSTox_RID_81207 |
| DTXSID9045895 | EINECS 247-400-3 | HMS2097F17 |
| HMS2235P08 | HY-B1071A | J-016217 |
| Lasalocid (sodium) | Lasalocid A Na salt | Lasalocid A Sodium |
| Lasalocid A Sodium Salt (Solution in acetonitrile 0.2mg/2ml) | Lasalocid A monosodium salt | Lasalocid A sodium 100 microg/mL in Acetonitrile |
| Lasalocid A sodium salt | Lasalocid A sodium salt solution, 100 mug/mL in acetonitrile, VETRANAL(TM), analytical standard; | Lasalocid A sodium salt solution, ~100 microg/ml in acetonitrile |
| Lasalocid sodium | Lasalocid sodium salt | Lascaloid |
| MCULE-6219687714 | MLS001173429 | MLS001304052 |
| MLS001334026 | MLS001334027 | MLS006011597 |
| MT 2007 | MT2007 | NCGC00095029-01 |
| NP167 | NSC 243046 | NSC243046 |
| Q27292230 | R987 | Ro 2-2985 |
| SMR000538906 | Sodium lasalocid | Sodium lasalocid A |
| Tox21_111396 | UNII-W2S5C71Y3G | W2S5C71Y3G |
| cid_6426773 | sodium;6-[(3R,4S,5S,7R)-7-[(2S,3S,5S)-5-ethyl-5-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyloxan-2-yl]-3-methyloxolan-2-yl]-4-hydroxy-3,5-dimethyl-6-oxononyl]-2-hydroxy-3-methylbenzoate |
| CAS Number | 25999-20-6 |
| PubChem Compound | 6426773 |